We observed the enhanced efficacy of CD33‐targeting RBCEVs loaded with ASOs in suppressing oncogenic FLT3‐ITD or miR‐125b levels in AML cells in vitro, resulting in a decreased cell viability. Here, CD33 is linked to acute myeloid leukemia.